Spaces:
Sleeping
Sleeping
| # 0009 CarePath Restructure Target Layout | |
| Date: 2026-07-13 | |
| ## Status | |
| Superseded in part by 0016 | |
| > Location update (2026-07-13): the approved Scribe training boundary now | |
| > resides at `scribe/training/`. The remaining Interpreter and shared-layout | |
| > decisions in this record remain accepted. | |
| ## Context | |
| CarePath serves two independent clinical workflows from one process, while the | |
| repository currently places their runtime, frontends, tests, evaluation, and | |
| training assets in mixed top-level locations. The approved restructure requires | |
| a durable target layout without changing import names, routes, or safety | |
| behavior. | |
| ## Decision | |
| Move runtime ownership into `scribe/` and `interpreter/`, and reserve `shared/` | |
| for the later shared package. Decision 0016 supersedes this record's original | |
| top-level GEC-training location. Keep the import names `carepath` and `app`, | |
| keep all public routes unchanged, and retain the root `pyproject.toml` as the | |
| Scribe distribution. Move the interpreter evaluation harness with | |
| `interpreter/`; it is not GEC training. | |
| Each relocation phase must update path math, packaging, CI, Docker, deployment | |
| documentation, and the affected product contracts, then pass its relevant | |
| existing proof before the next phase begins. | |
| ## Alternatives Considered | |
| 1. Leave the current mixed top-level layout. | |
| 2. Rename both runtime imports to match their new directory names. | |
| 3. Create separate Python distributions before the relocations. | |
| ## Consequences | |
| Positive: | |
| - Runtime and training ownership are visible from the repository layout. | |
| - Existing imports and public API routes remain stable. | |
| - The risk-evaluation suite stays with the Interpreter that it validates. | |
| Tradeoffs: | |
| - Relative path calculations and deployment files must be audited after every move. | |
| - The Vercel project root setting requires owner action when `scribe/frontend/` moves. | |
| ## Follow-Up | |
| - Record a separate high-risk Harness intake and trace for every phase. | |
| - Do not begin owner-led clinical-data collection without legal consent and data-handling approval. | |